Checking for airflow limitation in smokers attending cardiology clinics
A Multinational, Multicenter, Observational, Prospective Cohort Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics
AstraZeneca · NCT07315958
This project will test how common airflow limitation is among people aged 40 and older with at least 10 pack‑years of smoking who visit cardiology clinics in Turkey.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | AstraZeneca (industry) |
| Locations | 2 sites (Ankara and 1 other locations) |
| Trial ID | NCT07315958 on ClinicalTrials.gov |
What this trial studies
This observational study screens cardiology outpatients aged 40 and above with a smoking history of at least 10 pack‑years using spirometry and the COPD Assessment Test (CAAT). Patients are recruited at participating cardiology clinics in Ankara and Istanbul, provide written consent, complete the questionnaire, and undergo spirometry unless excluded for asthma or recent bronchodilator use. The primary goal is to estimate the prevalence of undiagnosed airflow limitation among smokers seen in cardiovascular outpatient settings. Results will be compared with regional COPD prevalence data to determine whether cardiology clinics are high‑yield sites for case-finding.
Who should consider this trial
Good fit: Adults aged 40 or older who attend the participating cardiology clinics, have a smoking history of at least 10 pack‑years, can complete spirometry and the CAAT questionnaire, and provide written consent.
Not a fit: People with a prior diagnosis of asthma, those who used a bronchodilator for an acute respiratory infection before spirometry, younger non‑smokers, or patients who do not attend the participating cardiology clinics are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could help clinicians find previously undiagnosed COPD in smokers seen at heart clinics so patients can get earlier treatment and support.
How similar studies have performed: Previous screening efforts in non‑pulmonary clinics have often found high rates of undiagnosed airflow limitation, so this approach is not entirely novel and has shown useful results in similar settings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged 40 years or older. 2. Patients with a smoking history of 10 pack-years or more. 3. Patients willing and able to complete pulmonary function test, using a spirometer. 4. Patients who have provided written consent to participate in the study. 5. Patients attending cardiology clinics at the participating centers. 6. Patients willing and able to complete the CAAT questionnaire. Exclusion Criteria: A. Patients diagnosed with bronchial asthma. B. Patients who used a bronchodilator for an acute respiratory infection before performing spirometry.
Where this trial is running
Ankara and 1 other locations
- Research Site — Ankara, Turkey (Türkiye) (RECRUITING)
- Research Site — Istanbul, Turkey (Türkiye) (RECRUITING)
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Respiratory, chronic obstructive pulmonary disease